Source：Molbase :https://jiage.molbase.cn/kuaibao/525/125272 2022-03-09
On March 8, Lonza announced the completion of a laboratory expansion at its active pharmaceutical ingredients (API) manufacturing site in Nansha, China.The expansion focuses on expanding the capacity of the development laboratory and kilogram cGMP manufacturing laboratory to provide a clinical supply of efficient API (HPAPI).
HPAPI represents an increasing portion of the small molecule pipeline with special requirements for equipment, process safety, containment and facility design.HPAPI currently forms a large part of Lonza's small molecule development pipeline, and the need for manufacturing is growing.The new laboratory is part of a recent investment aimed at expanding the medium manufacturing capacity of the Nansha (CN) plant and adding additional capacity to Lonza's global HPAPI manufacturing network to meet growing customer needs.
Jan Vertommen, Executive Director of Lonza Small Molecule Commercial Development, commented: "With more than 1,000 HPAPI in development, covering a wide range of indications, there is a growing demand for HPAPI development and manufacturing capabilities from early stage to commercialization.The new lab further strengthens our global HPAPI manufacturing services and we are pleased that our first customers in Europe and the United States have signed up for the HPAPI program for our new lab in Nansha."
The new lab further strengthens our global HPAPI manufacturing services and we are pleased that our first customers in Europe and the United States have signed up for the HPAPI program for our new lab in Nansha."The new lab will begin operations in March 2022.
Jason Zhang, Lonza's Director of small molecule API research and development, added: "The expansion of our HPAPI capabilities in Nansha enables us to enter HPAPI manufacturing to meet the growing global demand, especially in supporting oncology clinical trials.Our presence in Nansha allows us to leverage world-class, quality and reliable local suppliers of raw materials, thus further increasing the speed of problem solving and manufacturing."
The expanded capacity at Nansha will continue to support us in developing and manufacturing innovative therapies for our global customers and their patients.
Network source, infringement please contact delete
